Glycostem is going to present at the Cell Therapy Manufacturing and Gene Therapy Congress 2022 in Amsterdam.
6 Dec 2022, 11:35 (CET)
Scaling to Commercial Scale: Cord Blood Stem Cell Derived NK Cells
- presented by John Veluchamy, Senior Development Scientist
6 Dec 2022, 15:00 (CET)
Quality by Design for Cell Therapy Manufacturing
- presented by Valters Stelmanis, Regulatory Specialist
Glycostem CDO Volker Huppert is going to participate and lead a discussion at European Immuno-Oncology Xchange 2022 roundtable meeting on 23rd November 2022 in Zurich, Switzerland.
Topic: Cell Therapies going off-the-shelf: non-modified NK cells, CAR-NK cells, TCR-NK cells, combination therapies
Track: Next-Generation Therapies
Time: 16:15-17:15 (CET)
Glycostem CEO Troels Jordansen is attending the Jefferies London Healthcare Conference from 15th to 16th Nov 2022 in London. The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe.
Glycostem CEO Troels Jordansen is attending Inv€$tival Showcase in London, UK on 14 Nov 2022. Inv€$tival is an international showcase of early, growth stage and public life science and health technology companies.
Glycostem is going to present a poster at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA, USA.
Title: Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
Abstract Number: 245
Presentation and Session Information*
Annual Meeting Regular Poster Abstract Presenter: (245) Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
Poster Hall
11/10/2022 - 11/11/2022, 9:00 am - 9:00 pm
Presented by: Monica Raimo
Glycostem CDO Volker Huppert will be speaking at Cell Series UK conference on 7th - 8th November, 2022.